top of page

Caribou Biosciences’ CEO on working toward a pivotal trial in 2nd line LBCL

Rachel Haurwitz describes recent data and the durability profile of Caribou’s allogeneic CAR-T product as the company plans to discuss a pivotal trial design with FDA.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page